InflaRx (NASDAQ:IFRX) Rating Reiterated by HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 419.48% from the stock’s previous close.

InflaRx Price Performance

Shares of IFRX opened at $1.54 on Wednesday. The business’s 50-day moving average is $1.49 and its 200-day moving average is $1.50. InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $3.08. The company has a market capitalization of $90.68 million, a price-to-earnings ratio of -1.97 and a beta of 1.57.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.04 million. Equities research analysts expect that InflaRx will post -0.98 earnings per share for the current fiscal year.

Institutional Trading of InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC raised its position in InflaRx (NASDAQ:IFRX) by 2.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the period. Ikarian Capital LLC owned about 1.20% of InflaRx worth $1,086,000 as of its most recent filing with the SEC. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.